Steven Milwee

684 total citations
10 papers, 452 citations indexed

About

Steven Milwee is a scholar working on Oncology, Hepatology and Epidemiology. According to data from OpenAlex, Steven Milwee has authored 10 papers receiving a total of 452 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Hepatology and 4 papers in Epidemiology. Recurrent topics in Steven Milwee's work include Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Pancreatic and Hepatic Oncology Research (4 papers) and Renal cell carcinoma treatment (3 papers). Steven Milwee is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Pancreatic and Hepatic Oncology Research (4 papers) and Renal cell carcinoma treatment (3 papers). Steven Milwee collaborates with scholars based in United States, Italy and United Kingdom. Steven Milwee's co-authors include Nick Fotheringham, Steve Nelson, Richard K. Root, Robert F. Lodato, J. F. Cade, Jordi Rello, Antoní Torres, Jean‐Louis Vincent, Ward Patrick and Julie C. Lougheed and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Infectious Diseases and Critical Care Medicine.

In The Last Decade

Steven Milwee

10 papers receiving 443 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Steven Milwee United States 9 194 149 134 125 89 10 452
Sujit Mukherjee United Kingdom 8 162 0.8× 166 1.1× 48 0.4× 173 1.4× 110 1.2× 10 480
Rareș Crăciun Romania 13 83 0.4× 107 0.7× 62 0.5× 98 0.8× 26 0.3× 37 329
Su Rin Shin South Korea 9 121 0.6× 94 0.6× 116 0.9× 108 0.9× 18 0.2× 22 465
Young Mi Hong South Korea 11 148 0.8× 114 0.8× 86 0.6× 155 1.2× 12 0.1× 44 341
Chongtu Yang China 13 252 1.3× 100 0.7× 70 0.5× 360 2.9× 27 0.3× 58 656
Leeyen Hsu United States 9 181 0.9× 50 0.3× 56 0.4× 159 1.3× 115 1.3× 12 439
Po‐Da Chen Taiwan 12 93 0.5× 127 0.9× 117 0.9× 380 3.0× 33 0.4× 32 590
Nekisa Zakeri United Kingdom 8 194 1.0× 81 0.5× 32 0.2× 180 1.4× 175 2.0× 18 457
Akeel Alisa United Kingdom 9 167 0.9× 146 1.0× 39 0.3× 269 2.2× 164 1.8× 10 494
Hui Ye China 11 88 0.5× 115 0.8× 144 1.1× 63 0.5× 26 0.3× 24 502

Countries citing papers authored by Steven Milwee

Since Specialization
Citations

This map shows the geographic impact of Steven Milwee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Milwee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Milwee more than expected).

Fields of papers citing papers by Steven Milwee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Milwee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Milwee. The network helps show where Steven Milwee may publish in the future.

Co-authorship network of co-authors of Steven Milwee

This figure shows the co-authorship network connecting the top 25 collaborators of Steven Milwee. A scholar is included among the top collaborators of Steven Milwee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Milwee. Steven Milwee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
2.
El-Khoueiry, Anthony B., Tim Meyer, Ann‐Lii Cheng, et al.. (2020). SO-9 Outcomes for patients with advanced hepatocellular carcinoma and Child-Pugh B liver function in the phase 3 CELESTIAL study of cabozantinib vs placebo. Annals of Oncology. 31. S220–S220. 12 indexed citations
3.
Ryoo, Baek‐Yeol, Philippe Merle, Joong‐Won Park, et al.. (2020). Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. ESMO Open. 5(4). e000714–e000714. 61 indexed citations
4.
Kelley, Robin Kate, Ann‐Lii Cheng, Fadi S. Braiteh, et al.. (2019). Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy.. Journal of Clinical Oncology. 37(15_suppl). TPS4157–TPS4157. 26 indexed citations
5.
Abou‐Alfa, Ghassan K., Tim Meyer, Ann‐Lii Cheng, et al.. (2019). Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial.. Journal of Clinical Oncology. 37(15_suppl). 4088–4088. 19 indexed citations
6.
Escudier, Bernard, Thomas Powles, Robert J. Motzer, et al.. (2018). Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. Journal of Clinical Oncology. 36(8). 765–772. 121 indexed citations
7.
Kelley, Robin Kate, Baek‐Yeol Ryoo, Philippe Merle, et al.. (2018). Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 36(15_suppl). 4088–4088. 8 indexed citations
8.
Escudier, Bernard, Thomas Powles, Robert J. Motzer, et al.. (2016). Efficacy of cabozantinib (C) vs everolimus (E) in patients (pts) with advanced renal cell carcinoma (RCC) and bone metastases (mets) from the phase III METEOR study.. Journal of Clinical Oncology. 34(15_suppl). 4558–4558. 8 indexed citations
9.
Root, Richard K., Robert F. Lodato, Ward Patrick, et al.. (2003). Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis*. Critical Care Medicine. 31(2). 367–373. 130 indexed citations
10.
Nelson, Steve, Judy Stone, Michel G. Bergeron, et al.. (2000). A Randomized Controlled Trial of Filgrastim for the Treatment of Hospitalized Patients with Multilobar Pneumonia. The Journal of Infectious Diseases. 182(3). 970–973. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sujit Mukherjee Breakdown of academic impact, for papers by Rareș Crăciun Breakdown of academic impact, for papers by Su Rin Shin Breakdown of academic impact, for papers by Young Mi Hong Breakdown of academic impact, for papers by Chongtu Yang Breakdown of academic impact, for papers by Leeyen Hsu Breakdown of academic impact, for papers by Po‐Da Chen Breakdown of academic impact, for papers by Nekisa Zakeri Breakdown of academic impact, for papers by Akeel Alisa Breakdown of academic impact, for papers by Hui Ye
Rankless by CCL
2026